Copyright and Disclaimer Print  



     Alberta Regulation 155/2002

     Cancer Programs Act

     CANCER PROGRAMS AMENDMENT REGULATION

     Filed:  July 18, 2002

Made by the Minister of Health and Wellness (M.O. 65/2002) on July 16, 2002
pursuant to sections 16 and 22 of the Cancer Programs Act.


1   The Cancer Programs Regulation (AR 242/98) is amended by this
Regulation.


2   The Schedule is repealed and the following is substituted:

     SCHEDULE


Drug
Group
Dosage Form
Criteria


13 Cis-RETINOIC ACID
     2
capsules
Pediatrics
  restricted to the treatment of advanced stage neuroblastoma following
POG/CCG Protocols
  prescribing limited to written authorization by physicians recommended by
the pediatric tumour program


ALL-TRANS RETINOIC ACID
     2
capsules
 restricted to treatment of acute promyelocytic leukemia
 prescribing limited to written authorization by physicians recommended by
the hematology/lymphoma tumour program or the pediatric tumour program


AMSACRINE
     2
injectable



ANAGRELIDE
     1
capsules
 for thrombocytosis due to myeloproliferative disorder
 prescribing limited to written authorization by physicians recommended by
the hematology/lymphoma tumour program


ANASTROZOLE
     1
tablets
 alternative first line hormonal therapy for post menopausal women with
hormone positive, metastatic breast cancer


ASPARAGINASE
     2
injectable



BCG
     1
injectable
  bladder carcinoma


BICALUTAMIDE
     1
tablets
  restricted to patients who are intolerant to Nilutamide or Flutamide.
  approved dosage is 50 mg daily.


BLEOMYCIN
     1
     2
injectable
pump



BUSERELIN
     1
injectable
  prostate cancer
  Restricted to:
Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT).
Neoadjuvant use pre radical prostatectomy (4 months pre).
Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT).
Adjuvant use (3 years post RT).
Stage IV (N1-N3) (M1-M1c): As monotherpy in medical castration.
In total androgen blockade (medical castration and nonsteriodal
antiandrogen).
  Guidelines for LHRH use in the above stated stages include: LHRH agonists
are indicated for use in patients at risk of thromboembolic disease,
strokes (CVA), myocardial infarction and also for consideration in patients
with dyslipidemia, hypertension, diabetes mellitus or where a patient is
considered intolerant to cyproterone acetate or megestrol acetate.


BUSULFAN
     1
tablets



CAPECITABINE
     2









     2
oral









oral
  for use in anthracycline pretreated metastatic or advanced breast cancer
patients who may or may not have been previously treated with taxanes.
 prescribing limited to written authorization by physicians recommended by
the breast tumour program
 option in first line treatment of advanced or metastatic colorectal cancer
 prescribing limited to written authorization by named physicians as
recommended by the GI tumour program


CARBOPLATIN
     1
injectable



CARMUSTINE
     1
injectable



CHLORAMBUCIL
     1
tablets



CISPLATIN
     1
injectable



CLADRIBINE
     2
injectable
 restricted to treatment of hairy cell leukemia
 Waldenstrom's macroglobulinemia
 prescribing limited to written authorization by physicians recommended by
the hematology/lymphoma tumour program



     3
injectable
POG Protocol 9720
prescribing limited to written authorization by physicians recommended by
the pediatric tumour program


CLODRONATE
     1
oral
 treatment of osteolytic bone lesions in metastatic breast cancer


CYCLOPHOSPHAMIDE
     1
injectable, tablets



CYPROTERONE
     1
 tablets



CYTARABINE
     1
injectable



CYTARABINE LIPOSOMAL
     2
injectable
 for intrathecal management of neoplastic meningitis due to solid tumours
or lymphoma


DACARBAZINE
     1
injectable



DACTINOMYCIN
     1
injectable



DAUNORUBICIN
     1
injectable



DEXAMETHASONE
     1
injectable, tablets
  antiemetic use NOT covered


DOCETAXEL
     2
injectable
 treatment of metastatic breast cancer after failure of any previous
chemotherapy regimen.
 as a single agent or in combination, as an option for first line treatment
of metastatic breast cancer





 only one taxane is to be administered to any one patient
 prescribing limited to written authorization by named physicians as
recommended by the breast tumour program



     2
injectable
 2nd line therapy in patients with advanced or metastatic non-small cell
lung cancer having received prior platinum-based chemotherapy, good
performance status
 (ECOG 0-2), no brain metastases
 prescribing limited to written authorization by named physicians as
recommended by the lung tumour program


DOXORUBICIN
     1
injectable



DOXORUBICIN LIPOSOMAL
     2
injectable
  Kaposi's sarcoma



     2
injectable
 2nd or 3rd line treatment of ovarian cancer, fallopian tube carcinoma and
primary peritoneal neoplasms
 prescribing limited to written authorization by named physicians as
recommended by the gynecology tumour program


EPIRUBICIN
     2
injectable
 adjuvant (node positive) and neoadjuvant (stage II and III), treatment of
pre and post menopausal breast cancer patients
 prescribing limited to written authorization by named physicians as
recommended by the breast tumour program


ERWINIA ASPARAGINASE
     3
injectable
 restricted to use in patients hypersensitive to E. Coli asparaginase for
remission induction in acute lymphoblastic leukemia
 prescribing limited to written authorization by physicians recommended by
the pediatric tumour program
or the hematology/ lymphoma program


ESTRAMUSTINE
     1
capsules



ETOPOSIDE
     1
injectable, capsules



EXEMESTANE
     2
oral
 for hormonal treatment of advanced breast cancer in postmenopausal women
who have progressed following hormonal therapy
 prescribing limited to written authorization by named physicians as
recommended by the breast tumour program


FLUDARABINE
     2
injectable
 previously treated or untreated chronic lymphocytic leukemia
 low grade lymphoma
 Waldenstrom's macroglobulinemia
 prescribing limited to written authorization by physicians recommended by
the hematology/lymphoma tumour program


FLUOROURACIL
     1

     2
injectable, cream
pump



FLUTAMIDE
     1
tablets
  prostate cancer


GEMCITABINE
     2
injectable
Lung Cancer
 patients who have failed treatment with Vinorelbine or Paclitaxel
containing regimens or who are unable to tolerate treatment with these
agents.
 prescribing limited to written authorization by physicians recommended by
the lung tumour program



     2
injectable
Bladder Cancer
 Gemcitabine/Cisplatin as first line chemotherapy in locally
advanced/metastatic bladder cancer
 prescribing limited to written authorization by physicians recommended by
the GU tumour program



     2
injectable
Pancreas
 locally advanced or metastatic adenocarcinoma of the pancreas.
 prescribing limited to written authorization by physicians recommended by
the GI tumour program


GOSERELIN
     1
injectable
  prostate cancer
  Restricted to:
Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT).
Neoadjuvant use pre radical prostatectomy (4 months pre).
Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT).
Adjuvant use (3 years post RT).
Stage IV (N1-N3) (M1-M1c): As monotherpy in medical castration.
In total androgen blockade (medical castration and nonsteriodal
antiandrogen).
 Guidelines for LHRH use in the above stated stages include: LHRH agonists
are indicated for use in patients at risk of thromboembolic disease,
strokes (CVA), myocardial infarction and also for consideration in patients
with dyslipidemia, hypertension, diabetes mellitus or where a patient is
considered intolerant to cyproterone acetate or megestrol acetate.



     2
injectable
  breast cancer.  2nd line hormonal therapy for recurrent or metastatic
disease in estrogen and/or progesterone receptor positive pre and
perimenopausal patients after tamoxifen failure.
 prescribing limited to written authorization by physicians recommended by
the breast tumour program


HYDROCORTISONE SODIUM SUCCINATE

     1

injectable

  intrathecal use only


HYDROXYUREA
     1
capsules



IDARUBICIN
     3
injectable
POG Protocol 9720
prescribing limited to written authorization by physicians recommended by
the pediatric tumour program


IFOSFAMIDE
     1
     2
injectable
pump



INTERFERON


  - alpha 2a or 2b

  - alpha 2b in new patients "02-03"
     1
injectable
  cladribine-resistant hairy cell leukemia
  Kaposi's sarcoma
  chronic myelogenous leukemia
  metastatic renal cell carcinoma



INTERFERON
  alpha 2a ONLY
     1
injectable
 mycosis fungoides and sezary syndrome (cutaneous T-cell lymphomas)
 prescribing limited to written authorization by physicians recommended by
the hematology/lymphoma tumour program


INTERFERON
 alpha 2b ONLY
     1





     2
injectable





injectable
 basal cell carcinoma
 adjuvant treatment of high risk melanoma
 2nd line therapy of superficial bladder cancer

 treatment of patients with malignant carcinoid and neuroendocrine
gastroenteropancreatic tumours not amenable to surgical extirpation
 prescribing limited to written authorization by physicians recommended by
the GI and endocrine tumour programs



     2
injectable
 maintenance therapy in multiple myeloma patients who have achieved
complete remission after high dose chemotherapy and autologous stem cell
transplant.
 follicular lymphoma and need for therapy as indicated by any of: mass >7
cm or 3 sites >3 cm, Bsx, splenomegaly @ umbilicus, compression syndromes
(GI, GU, orbit), effusions cytopenias, Age < 70 yo
 prescribing limited to written authorization by physicians recommended by
the hematology/lymphoma tumour program.


IRINOTECAN

*  NOTE:
Loperamide supplied by industry with this agent's use
     2










     2
injectable










injectable
Metastatic Colorectal Cancer
 first line (with 5FU and leucovorin).
 2nd line after 5FU based chemo.
 prescribing limited to written authorization by physicians recommended by
the GI tumour program.

Pediatrics
 restricted to the treatment of high risk metastatic rhabdomyosarcomas
following POG/CCG protocols
 prescribing limited to written authorization by physicians recommended by
the pediatric tumour program.


LETROZOLE
     1
tablets
 2nd line hormonal therapy for postmenopausal metastatic breast cancer
 may be given first line in those patients with metastatic hormone receptor
positive postmenopausal disease who are at risk of a thromboembolic event
(history of previous thromboembolic event).


LEUCOVORIN CALCIUM
     1
injectable, tablets
 rescue therapy for methotrexate only
 in combination with 5FU


LEUPROLIDE
     1
injectable
  prostate cancer
  Restricted to:
Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT).
Neoadjuvant use pre radical prostatectomy (4 months pre).
Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT).
Adjuvant use (3 years post RT).
Stage IV (N1-N3) (M1-M1c): As monotherpy in medical castration.
In total androgen blockade (medical castration and nonsteriodal
antiandrogen).





  Guidelines for LHRH use in the above stated stages include: LHRH agonists
are indicated for use in patients at risk of thromboembolic disease,
strokes (CVA), myocardial infarction and also for consideration in patients
with dyslipidemia, hypertension, diabetes mellitus or where a patient is
considered intolerant to cyproterone acetate or megestrol acetate.


LOMUSTINE
     1
capsules



MECHLORETHAMINE
     1
injectable, topical



MEDROXYPROGESTERONE ACETATE
     1
tablets, injectable



MEGESTROL ACETATE
     1
tablets



MELPHALAN
     1
tablets



MERCAPTOPURINE
     1
tablets



MESNA
     1
injectable



METHOTREXATE
     1
injectable, tablets



MITOMYCIN
     1
injectable
NOTE:  3rd line for bladder cancer indication


MITOXANTRONE
     1
injectable



NANDROLONE DECANOATE
     1
injectable



NILUTAMIDE
     1
tablets
  prostate cancer


PACLITAXEL
     2
injectable
Ovarian Cancer
 first line treatment of ovarian cancer (irrespective of the stage of
disease or amount of residual disease), fallopian tube carcinoma, primary
peritoneal neoplasms, and papillary serous and clear cell endometrial
carcinomas
 prescribing limited to written authorization by physicians recommended by
the gynecology tumour program



     2
injectable
Lung Cancer
 prescribing limited to written authorization by physicians recommended by
the lung tumour program



     2
injectable
Breast Cancer
 restricted to the treatment of metastatic breast cancer when no response
to anthracycline (doxorubicin, epirubicin, or mitoxantrone) containing
regimen. Relapse within 1 year after completion of adjuvant chemotherapy
including an anthracycline. First assessment of efficacy after 2 courses
 only one taxane is to be administered to any one patient
 prescribing limited to written authorization by physicians recommended by
the breast tumour program



     2
injectable
Endometrial Cancer
 restricted for use in metastatic, advanced or recurrent endometrial cancer
 prescribing limited to written authorization by named physicians as
recommended by the gynecology tumour program



     2
injectable
Testes
 2nd line regimen for relapsed germ cell tumours of the testes



     2
injectable
 in combination chemotherapy for unknown primary metastatic adenocarcinoma
 prescribing limited to written authorization by named physicians as
recommended by the breast and hematology tumour programs


PAMIDRONATE
     1
injectable
 treatment of multiple myeloma


PEG ASPARAGINASE
     3
injectable
 prescribing limited to written authorization by physicians recommended by
the pediatric tumour program as per POG protocols


PREDNISOLONE SODIUM PHOSPHATE
     1
liquid
 first line agent for pediatric patients under 7 years of age
 2nd-line agent for pediatric patients 7 years and older unable to tolerate
prednisone tablets


PREDNISONE
     1
tablets



PROCARBAZINE
     1
capsules



RALTITREXED
     2
injectable
 treatment of metastatic colorectal cancer
NOTE:  Because there is a possibility that FUFA may provide slightly
superior survival, FUFA should remain the first choice for younger, fitter
patients.  Raltitrexed may be considered the treatment of choice in elderly
patients (over age 70), patients who have experienced severe mucositis with
FUFA despite one stage of dose reduction, or in patients with late relapse
after adjuvant treatment where the adjuvant 5FU based treatment was poorly
tolerated with documented reason for intolerance.
 prescribing limited to written authorization by physicians recommended by
the GI tumour program


RITAXIMAB
     2
injectable
 relapsed or refractory follicular lymphoma
 prescribing limited to written authorization by physicians recommended by
the lymphoma tumour program



     2
injectable
 in combination with CHOP for aggressive histology B-cell CD20 positive
non-hodgkin's lymphoma in patients 60 years of age or older
 prescribing limited to written authorization by named physicians as
recommended by the hematology/lymphoma tumour program


STREPTOZOCIN
     1
injectable



TAMOXIFEN
     1
tablets



TEMOZOLOMIDE
     2
oral
  first-line treatment of recurrent glioblastoma multiforme and anaplastic
astrocytoma
  prescribing limited to written authorization by physicians recommended by
the neuro oncology tumour program


TENIPOSIDE
     1
injectable



THALIDOMIDE
     3
oral
 in refractory multiple myeloma
 Special Access Program, Health Protection Branch
 prescribing limited to written authorization by named physicians as
recommended by the lymphoma tumour program


THIOGUANINE
     1
tablets



THIOTEPA
     2
injectable



TOPOTECAN
     2
injectable
Ovarian
 advanced epithelial ovarian cancer as 2nd line therapy
 prescribing limited to written authorization by physicians recommended by
the gynecology tumour program
Pediatrics
  restricted to the treatment of advanced stage neuroblastoma following
POG/CCG Protocols
 restricted to the treatment of intermediate risk rhabdomyosarcoma
following POG/CCG protocols
  prescribing limited to written authorization by physicians recommended by
the pediatric tumour program


TRASTUZUMAB
     2
injectable
Metastatic Breast
 restricted to the treatment of metastatic breast cancer, HER 2 protein
overexpression (+3)
 prescribing limited to written authorization by physicians recommended by
the breast tumour program


VINBLASTINE
     1
injectable



VINCRISTINE
     1
injectable



VINORELBINE
     2
injectable
Lung Cancer
 restricted to the treatment of metastatic non-small cell lung cancer with
an ECOG score of 2 or better.
 prescribing limited to written authorization by physicians recommended by
the lung tumour program



     2
injectable
Metastatic Breast
 first line therapy for elderly patients (over 65 years of age) and 2nd or
3rd line therapy for metastatic breast cancer.  Assess response after 2
cycles.
 prescribing limited to written authorization by physicians recommended by
the breast tumour program


     ------------------------------

     Alberta Regulation 156/2002

     Safety Codes Act

     BOILERS AND PRESSURE VESSELS EXEMPTION AMENDMENT ORDER

     Filed:  July 22, 2002

Made by the Minister of Municipal Affairs (M.O. P:004/02) on July 13, 2002
pursuant to section 2(2) of the Safety Codes Act.


1   The Boilers and Pressure Vessels Exemption Order (AR 300/94) is amended
by this Order.


2   The following is added after section 3:

Expiry
     3.1   For the purpose of ensuring that this Order is reviewed for
ongoing relevancy and necessity, with the option that it may be repassed in
its present or an amended form following a review, this Order expires on
March 31, 2004.


     Alberta Regulation 157/2002

     Safety Codes Act

     BOILERS AND PRESSURE VESSELS AMENDMENT REGULATION

     Filed:  July 23, 2002

Made by the Lieutenant Governor in Council (O.C. 349/2002) on July 23, 2002
pursuant to section 65 of the Safety Codes Act.


1   The Boilers and Pressure Vessels Regulation (AR 293/94) is amended by
this Regulation.


2   The heading "COMMENCEMENT" preceding section 10 is repealed and the
heading "EXPIRY AND COMING INTO FORCE" is substituted.


3   The following is added before section 10:

Expiry
     9.1   For the purpose of ensuring that this Regulation is reviewed
for ongoing relevancy and necessity, with the option that it may be
repassed in its present or an amended form following a review, this
Regulation expires on March 31, 2004.


     ------------------------------

     Alberta Regulation 158/2002

     Safety Codes Act

     DESIGN, CONSTRUCTION AND INSTALLATION OF BOILERS
     AND PRESSURE VESSELS AMENDMENT REGULATION

     Filed:  July 23, 2002

Made by the Lieutenant Governor in Council (O.C. 350/2002) on July 23, 2002
pursuant to section 65 of the Safety Codes Act.


1   The Design, Construction and Installation of Boilers and Pressure
Vessels Regulations (AR 227/75) are amended by this Regulation.


2   Section 1 is amended

     (a)  in clause (a) by striking out "Boilers and Pressure Vessels
Act" and substituting "Safety Codes Act";

     (b)  by repealing clauses (e), (g) and (g.1).


3   Section 2 is amended

     (a)  in subsection (1) by striking out the words preceding clause
(a) and substituting the following:

     2(1)  The following are exempt from this Regulation and the Boilers
and Pressure Vessels Regulation (AR 293/94):

     (b)  in subsection (2) by striking out "a certificate of inspection
under section 18(3) of the Act" and substituting "an
inspection/certification permit under section 6 of the Boilers and Pressure
Vessels Regulation (AR 293/94)".


4   Section 3(1) is amended by striking out "5, 6 and 18(1)(a) of the Act"
and substituting "4 and 5 of the Boilers and Pressure Vessels Regulation
(AR 293/94)".


5   Section 4 is amended

     (a)  in subsection (1) by striking out the words preceding clause
(a) and substituting the following:

     4(1)  Pressure equipment that contains or is intended to contain an
expansible fluid under pressure, has a capacity of 0.0425 m3 or less and is
of a type or class listed below is subject to sections 4 and 5 of the
Boilers and Pressure Vessels Regulation (AR 293/94) as if it is a pressure
vessel as defined in that Regulation:

     (b)  by repealing subsection (2) and substituting the following:

     (2)  Pressure equipment that contains or is intended to contain an
expansible fluid under pressure, has a capacity of 0.0425 m3 or less, and
that is not of a type or class listed in subsection (1) is subject to
sections 4 and 5 of the Boilers and Pressure Vessels Regulation (AR 293/94)
as if it is a fitting as defined in that Regulation.


6   Section 6(1) is amended by striking out "In accordance with section 5
of the Act, where" and substituting "Where".


7   Section 7(1) is amended by striking out "In accordance with section 5
of the Act, where" and substituting "Where".


8   Section 9 is amended by striking out "In accordance with section 6 of
the Act, any" and substituting "Any".


9   Section 11(1) is amended by striking out "In accordance with section 7
of the Act, where" and substituting "Where".


10   The following are repealed:

          Part 4;
          section 33.1(3);
          section 38;
          section 39;
          section 43(7) and (8);
          section 55;
          section 55.1;
          section 56.


11   Section 47.1 is amended

     (a)  in subsection (1) by repealing clause (a) and substituting the
following:

               (a)  "authority having jurisdiction" has the same
meaning as in the Alberta Fire Code 1997,    declared in force by the
Fire Code Regulation (AR 52/98); 

     (b)  in subsection (2) by striking out "fire authority for approval
by the fire authority" and substituting "authority having jurisdiction for
approval".


12   Section 60 is amended by striking out "Fire Prevention Act" and
substituting "Act".


13   The following is added after section 61:

Expiry
     62   For the purpose of ensuring that this Regulation is reviewed for
ongoing relevancy and necessity, with the option that it may be repassed in
its present or an amended form following a review, this Regulation expires
on March 31, 2004.


     Alberta Regulation 159/2002

     Safety Codes Act

     PLUMBING CODE AMENDMENT REGULATION

     Filed:  July 23, 2002

Made by the Lieutenant Governor in Council (O.C. 351/2002) on July 23, 2002
pursuant to section 65 of the Safety Codes Act.


1   The Plumbing Code Regulation (AR 219/97) is amended by this Regulation.


2   Section 1(1) is amended by adding the following after clause (a):

     (a.1)     "certification body" means an organization accredited or
recognized by the Standards Council of Canada as a certification body;


3   Section 2(1) is amended

     (a)  in clauses (a) and (b) by striking out "organization accredited
by the Standards Council of Canada" and substituting "body";

     (b)  in clause (b) by striking out "the certification organization"
and substituting "the certification body".


4   Section 3(3) is amended by striking out "1990" and substituting "1997".


5   Sections 4 and 5 are repealed and the following is substituted:

Effect of codes
     4   The Code referred to in, and as varied by, section 3, and any
codes or standards referenced in that Code, do not make or imply any
assurance or guarantee by the Crown in right of Alberta with respect to the
life expectancy, durability or operating performance of equipment or
materials referenced in the codes or standards.


     Alberta Regulation 160/2002

     Government Organization Act

     RADIATION HEALTH ADMINISTRATION AMENDMENT REGULATION

     Filed:  July 23, 2002

Made by the Lieutenant Governor in Council (O.C. 352/2002) on July 23, 2002
pursuant to Schedule 10, section 2 of the Government Organization Act.


1   The Radiation Heath Administration Regulation (AR 49/96) is amended by
this Regulation.


2   Section 2 is amended

     (a)  in subsection (1) by striking out "(4), (6) and (8)" and
substituting "(5), (7) and (9)";

     (b)  in subsection (3) by striking out "section 10(7)" and
substituting "section 10(8)";

     (c)  in subsection (6) by striking out "section 16(2)" and
substituting "section 16(3)".


3   Section 7(1) is amended by striking out "(Alta. Reg. 57/95)" wherever
it occurs and substituting "(AR 224/2001)".


4   Schedules 1 and 2 are repealed and the attached Schedules 1 and 2 are
substituted.

     SCHEDULE 1
     (Organizations)


ROW
COLUMN 1
COLUMN 2
COLUMN 3


1
College of Physicians and Surgeons of Alberta
Therapeutic or diagnostic x-ray equipment;
Therapy simulator equipment;
Cabinet x-ray equipment;
Class 3b and 4 lasers;
Particle accelerators;
Diffraction and analysis x-ray equipment
Installed or operated within private and public medical facilities, public
dental facilities, medical education facilities and podiatry facilities



2
Alberta Dental Association
Diagnostic x-ray equipment;
Class 3b and 4 lasers
Installed or operated within dental facilities, including dental education
facilities, but excluding dental facilities owned by a Regional Health
Authority


3
University of Calgary
Cabinet x-ray equipment;
Class 3B and 4 lasers;
Diffraction and analysis x-ray equipment;
Industrial radiographic and fluoroscopic x-ray equipment;
Irradiation x-ray equipment;
Particle accelerators;
Therapeutic or diagnostic x-ray equipment;
Computed tomography equipment;
Baggage inspection x-ray equipment;
Security x-ray equipment
Installed or operated within non-medical facilities owned or operated by
the University of Calgary and research, education, industrial, commercial,
entertainment and other health related facilities


4
College of Chiropractors of Alberta
Diagnostic x-ray equipment;
Class 3b and 4 lasers
Installed or operated within chiropractic facilities


5
Alberta Veterinary Medical Association
Diagnostic x-ray equipment;
Class 3b and 4 lasers
Installed or operated within veterinary clinics and veterinary education
facilities


6
University of Alberta
Cabinet x-ray equipment;
Class 3b and 4 lasers;
Diffraction and analysis x-ray equipment;
Therapeutic or diagnostic x-ray equipment;
Particle accelerators
Installed or operated within non-medical facilities owned or operated by
the University of Alberta










     SCHEDULE 2
     (Agencies)


ROW
COLUMN 1
COLUMN 2
COLUMN 3


1
Alberta Radiation Service
Box 1533
Cardston, AB
T0K 0K0
Diagnostic or therapeutic x-ray equipment; Class 3b and 4 lasers
Installed or operated within dental, medical, chiropractic, veterinary,
physical therapy, education, industrial, commercial, research and
entertainment facilities


2
RadMan Radiation Management Services Ltd.
4536 Stanley Drive SW
Calgary, AB
T2S 2R9
Diagnostic or therapeutic x-ray equipment;
Cabinet x-ray equipment;
Class 3b and 4 lasers
Installed or operated within dental,  medical, chiropractic, veterinary,
physical therapy, education, industrial, commercial, research and
entertainment facilities


3
B&P Stewart Ent. Ltd.
19-51263 Range Rd 204
Sherwood Park, AB
T8G 1E9
Diagnostic or therapeutic x-ray equipment

Installed or operated within dental, medical, chiropractic, veterinary and
education facilities


4
University of Calgary
Safety Services
2500 University Drive NW
Calgary, AB
T2N 1N4
Cabinet x-ray equipment;
Diffraction and analysis x-ray equipment;
Industrial radiographic and fluoroscopic x-ray equipment;
Class 3b and 4 lasers;
Diagnostic x-ray equipment;
Computed tomography equipment

Installed or operated within education, research and veterinary facilities
owned or operated by the University of Calgary



5
University of Alberta
Office of Environmental Health and Safety
Edmonton, AB T6G 2R5
Diagnostic x-ray equipment;
Cabinet x-ray equipment;
Diffraction and analysis x-ray equipment;
Class 3b and 4 lasers;
Particle accelerators
Installed or operated within education, research, dental and veterinary
facilities owned or operated by the University of Alberta


6
Calgary Health Region
Diagnostic Imaging
1403-29 Street NW
Calgary, AB
T2N 2T9
Diagnostic or therapeutic x-ray equipment;
Cabinet x-ray equipment;
Diffraction and analysis x-ray equipment;
Class 3b and 4 lasers;
Computed tomography equipment
Installed or operated within medical, dental and physical therapy
facilities


7
Capital Health Authority
Imaging Services
8440-112 St
Edmonton, AB T6G 2B7
Diagnostic or therapeutic x-ray equipment;
Cabinet x-ray equipment;
Diffraction and analysis x-ray equipment;
Computed tomography equipment
Installed or operated within medical, dental and physical therapy
facilities


8
David Thompson Regional Health Authority Diagnostic Imaging
3942-50A Avenue
Red Deer, AB
T4N 4E7
Diagnostic or therapeutic x-ray equipment
Installed or operated within medical and dental facilities owned or
operated by the David Thompson Regional Health Authority


9
Filipow Associates Inc.
6508-109 Avenue
Edmonton, AB T6A 1S2
Diagnostic or therapeutic x-ray equipment;
Computed tomography equipment;
Diffraction and analysis x-ray equipment;
Cabinet x-ray equipment;
Baggage inspection x-ray equipment;
Security x-ray equipment;
Irradiation x-ray equipment
Installed or operated within medical, dental, chiropractic, veterinary,
education and commercial facilities


10
Alberta Cancer Board Provincial Radiation Safety Office
Room 4027
11560 University Avenue
Edmonton, AB T6G 1Z2
Diagnostic or therapeutic x-ray equipment;
Therapy simulator x-ray equipment;
Computed tomography equipment;
Particle accelerators;
Cabinet x-ray equipment;
Class 3b and 4 lasers
Installed or operated within medical, dental and research facilities owned
or operated by the Alberta Cancer Board



     ------------------------------

     Alberta Regulation 161/2002

     Victims of Crimes Act

     VICTIMS' BENEFITS AMENDMENT REGULATION

     Filed:  July 23, 2002

Made by the Lieutenant Governor in Council (O.C. 354/2002) on July 23, 2002
pursuant to section 17 of the Victims of Crimes Act.


1   The Victims' Benefits Regulation (AR 201/97) is amended by this
Regulation.


2   Section 8 is amended by striking out "November 1, 2002" and
substituting "December 31, 2003".


     ------------------------------

     Alberta Regulation 162/2002

     Victims of Crimes Act

     VICTIMS' PROGRAMS AMENDMENT REGULATION

     Filed:  July 23, 2002

Made by the Lieutenant Governor in Council (O.C. 355/2002) on July 23, 2002
pursuant to section 17 of the Victims of Crimes Act.


1   The Victims' Programs Regulation (AR 135/97) is amended by this
Regulation.


2   Section 8 is amended by striking out "August 1, 2002" and substituting
"December 31, 2003".


     ------------------------------

     Alberta Regulation 163/2002

     Government Organization Act

     DESIGNATION AND TRANSFER OF RESPONSIBILITY
     AMENDMENT REGULATION

     Filed:  July 23, 2002

Made by the Lieutenant Governor in Council (O.C. 356/2002) on July 23, 2002
pursuant to section 16 of the Government Organization Act.


1   The Designation and Transfer of Responsibility Regulation (AR 44/2001)
is amended by this Regulation.


2   Section 5(5)(b) is repealed and the following is substituted:

     (b)  in Schedule 3 of the Community Development Grants Regulation
(AR 57/98) are transferred to the responsibility of the Minister of Gaming,
and


     ------------------------------

     Alberta Regulation 164/2002

     Alberta Treasury Branches Act

     ALBERTA TREASURY BRANCHES AMENDMENT REGULATION

     Filed:  July 23, 2002

Made by the Lieutenant Governor in Council (O.C. 360/2002) on July 23, 2002
pursuant to section 34 of the Alberta Treasury Branches Act.


1   The Alberta Treasury Branches Regulation (AR 187/97) is amended by this
Regulation.


2   Section 1(2) is amended

     (a)  by repealing clause (c) and substituting the following:

               (c)  "financial leasing corporation" means a corporation
that enters into or acquires agreements as defined in section 5.1;

     (b)  by repealing clause (d) and substituting the following:

               (d)  "information management corporation" means a
corporation whose activities are limited to

                         (i)  the collection, manipulation and
transmission of information,

                         (ii) the design, development, marketing and
sale of computer software,

                         (iii)     the provision of advisory and other
services related to the design and development of information management
systems,

                         (iv) the design, development, marketing and
sale of equipment integral to information management systems, and

                         (v)  the design, development, management,
manufacturing, marketing and sale of data transmission services,
information sites, communication devices and information platforms or
portals,

                    in respect of information that is primarily
financial or economic in nature or information that relates to the business
of Alberta Treasury Branches or of a corporation in which Alberta Treasury
Branches beneficially owns shares pursuant to section 19(4) of the Act;


3   The following is added after section 2:

Prescribed corporation
     2.1  A financial leasing corporation is a prescribed corporation for
the purposes of section 19(4)(l) of the Act.


4  The following is added after section 5:

Leasing and related agreements
     5.1(1)  In this section,

               (a)  "agreement" means

                         (i)  a security agreement as defined in the
Personal Property Security Act, or

                         (ii) a financial lease agreement, being an
agreement for a lease of personal property in which credit is extended by
the lessor to the lessee for the purpose of enabling the lessee to meet the
lessee's obligations under the lease;

               (b)  "property" means the personal property to which an
agreement relates.

     (2)  Alberta Treasury Branches may not beneficially own shares in a
financial leasing corporation unless

               (a)  the aggregate of

                         (i)  the book value of all of the property
that is subject to agreements held by the corporation, and

                         (ii) all amounts owing as receivables in
respect of such agreements

                    is equal to at least 80% of the assets of the
corporation, and

               (b)  the corporation meets the requirements of the
agreements.

     (3)  A financial leasing corporation may enter into or acquire
agreements only if the following requirements are met:

               (a)  the corporation shall not direct its customers or
potential customers to particular dealers in the property;

               (b)  at no time may the aggregate of the estimated
residual values of all the property of the corporation, excluding motor
vehicles, leased under the financial lease agreements exceed 10% of the
aggregate of the costs of acquisition of that leased property to the
corporation;

               (c)  the estimated residual value of property leased
under a financial lease agreement must not exceed 20% of its cost of
acquisition to the corporation;

               (d)  the agreement must be entered into or acquired for
the purpose of extending credit to the lessee or purchaser;

               (e)  the property that is the subject of the agreement
must be selected by the lessee or buyer and 

                         (i)  must be acquired by the corporation at
the request of the lessee or buyer, or

                         (ii) must have been acquired by the
corporation through the operation of an earlier agreement;

               (f)  the agreement must yield a return that

                         (i)  will compensate the corporation for not
less than its full investment in the property,

                         (ii) is reasonable, taking into account

                                   (A)  the term of agreement and
the other terms and conditions of it,

                                   (B)  the technological
obsolescence of the property, and

                                   (C)  the rate of return sought
by the other lessors in respect of similar agreements in respect of similar
property and under the same terms and conditions,

                         and

                         (iii)     is calculated by taking into account

                                   (A)  rental charges paid by the
lessee or purchaser,

                                   (B)  estimated tax benefits of
the agreement to the corporation, including tax credits and capital cost
allowance claims, and

                                   (C)  the amount of,

                                             (I)  where the
lessee or purchaser or a third party who is dealing at arm's length with
the corporation has, on or before the commencement of the agreement,
contracted to purchase the property or unconditionally guaranteed the
resale value of the property at the date of expiry of the agreement, the
purchase price or the resale value so guaranteed, or

                                             (II) in any other
case, but subject to clause (c), the estimated residual value of the
property;

               (g)  the agreement must contain a provision

                         (i)  assigning and conveying to the lessee
or purchaser the benefit of all warranties, guarantees or other
undertakings made by a manufacturer or supplier relating to property, or

                         (ii) setting out the responsibilities of the
corporation with regard to the warranties, guarantees or other undertakings
referred to in subclause (i);

               (h)  the agreement must substantially transfer to the
lessee or purchaser the benefits and risks incidental to the operation of
the property and must not place responsibility on the part of the
corporation to install, promote, service, clean, maintain or repair the
property;

               (i)  where the lessee or purchaser defaults in the
manner set out in the agreement and the default is not waived or the
agreement, including any renewals or extensions of it, expires, the
corporation shall

                         (i)  liquidate its interest in the property,
or

                         (ii) enter into a new agreement in respect
of that property within 2 years of that default or expiry or, where
proceedings in respect of that property have prevented the corporation from
complying with that requirement within that period, within 2 years of the
completion of those proceedings.

     (4)  An agreement may be renewed on its expiry and may be extended
during its terms.

     (5)  The financial leasing corporation shall not enter into an
agreement in respect of

               (a)  a motor vehicle having a gross vehicle weight of
less than 21 tonnes, or

               (b)  personal household property.

     (6)  For the purposes of subsection (5),

               (a)  "gross vehicle weight" means, in respect of a motor
vehicle, the gross vehicle weight that is specified by the manufacturer of
the motor vehicle as the loaded weight of the motor vehicle, or in the case
of a motor vehicle designed to pull a trailer, the motor vehicle with the
trailer;

               (b)  "personal household property" means personal
property that is leased by an individual pursuant to a financial lease
agreement or purchased by an individual pursuant to a conditional sales
agreement and intended primarily for the personal use or enjoyment of the
lessee or purchaser or of an individual who is not dealing at arm's length
with the lessee or purchaser.


5   Section 8(5) is amended

     (a)  by repealing clause (k) and substituting the following:

               (k)  demand loans at book value, other than loans to an
individual, that are fully secured by any of the following securities:

                         (i)  at market value, Treasury Bills of the
Government of Canada or of a province;

                         (ii) at book value, term deposits or other
similar instruments issued by a financial institution that mature within
100 days after the applicable date;

                         (iii)     at market value, bankers acceptances
that mature within one year from the date of issue and bearer deposit
notes;

                         (iv) at market value, commercial paper that
matures within 90 days from the date of issue and has at least one of the
short-term ratings referred to in the table in section 10(3);

                         (v)  at market value, securities, other than
securities referred to in clause (i), that are issued or guaranteed by the
Government of Canada, the government of a province or a municipality;

     (b)  by adding the following after clause (k):

               (l)  a line of credit to a participant in the Large
Value Transfer System that has at least one of the commercial paper credit
ratings referred to in the table in section 10(3).


6   The following is added after section 9.1:

Extra-provincial syndicated loan agreements
     9.2(1)  In this section, "Canadian corporation" means a corporation

               (a)  incorporated or continued in a jurisdiction in
Canada, outside of Alberta, and

               (b)  whose head office is outside of Alberta.

     (2)  Subject to subsection (3), Alberta Treasury Branches may enter
into a syndicated loan agreement with one or more financial institutions in
respect of a Canadian corporation if the corporation operates in Alberta.

     (3)  Alberta Treasury Branches's participation in syndicated loan
agreements under subsection (2) must not exceed in the aggregate 10% of the
total amount of commercial loans made by Alberta Treasury Branches at any
one time.


7   Section 10 is amended

     (a)  in subsection (1)

               (i)  by adding "derivative contracts, including" after
"into";

               (ii) by striking out "or rate" and substituting "and
rate";

     (b)  by repealing subsection (2) and substituting the following:

     (2)  Alberta Treasury Branches may enter into a transaction listed in
subsection (1) with an existing customer of Alberta Treasury Branches only
where

               (a)  the purpose of the transaction is to hedge against
risks of the customer relating to interest rates, commodity prices or
exchange rates, and

               (b)  if the purpose of the transaction is to hedge
against risks of the customer relating to commodity prices, Alberta
Treasury Branches takes an opposite position in the market to offset the
risk it assumes under the transaction.

     (c)  by adding the following after subsection (2.1):

     (2.2)  Alberta Treasury Branches may, for asset-liability management
purposes, negotiate the replacing or unwinding of existing derivative
contracts.

     (2.3)  Alberta Treasury Branches may enter into credit derivative
contracts with financial institutions in Canada that have at least one of
the credit ratings referred to in the table in subsection (3) in respect of
residential mortgage loans made under section 9 for the purpose of
diversifying its geographic concentration risk.

     (d)  in subsection (3)

               (i)  by striking out "a rating in accordance with" and
substituting "at least one of the ratings referred to in";

               (ii) by repealing the table and substituting the
following:

     Table of Securities Ratings

Rating Organization Long-term Rating    Short-term Rating

Standard and Poor's AA-  A-1(High)
Moody's Investors Service     Aa3  P-1
Dominion Bond Rating Service  AA(Low)   R-1(Mid)


8   Section 11 is amended by adding the following after subsection (4):

     (5)  Notwithstanding subsection (1), once Alberta Treasury Branches
becomes fully capitalized in the opinion of the Minister, the base fee with
respect to a particular fiscal year is

               (a)  in the case of deposits not greater than $60 000,
the lesser of 

                         (i)  an amount equal to the total of those
deposits held by Alberta Treasury Branches at the end of the fiscal year,
as shown in Alberta Treasury Branches' audited financial statements,
multiplied by Canada Deposit Insurance Corporation's rate for a
deposit-taking institution with a similar risk profile as Alberta Treasury
Branches, as determined by the Minister, and

                         (ii) an amount equal to 1/6 of 1% of all
those deposits held by Alberta Treasury Branches at the end of the fiscal
year, as shown in Alberta Treasury Branches' audited financial statements;

               (b)  in the case of deposits greater than $60 000, an
amount equal to 1/6 of 1% of all those deposits held by Alberta Treasury
Branches at the end of the fiscal year, as shown in Alberta Treasury
Branches' audited financial statements.

     (6)  For the purposes of applying the rates in subsection (5), the
Minister may accept an estimate prepared by Alberta Treasury Branches of
the amount of deposits greater than $60 000 if that amount is not reported
in Alberta Treasury Branches' audited financial statements.


9   The following is added after section 23:


Compliance with guidelines
     23.1(1)  The board shall establish guidelines, satisfactory to the
Minister, related to investments, lending and capital adequacy.

     (2)  Alberta Treasury Branches shall provide to the Minister annually
on or before the date on which it submits its annual financial statements
to the Minister under section 23 of the Act, an audited report on its
compliance with the guidelines referred to in subsection (1), in the form
prescribed by the Minister.


10   Section 29 is repealed and the following is substituted:

Liquidity investments
     29   Alberta Treasury Branches shall have and keep available
unencumbered liquid assets in accordance with the guidelines referred to in
section 23.1.


11   Section 30 is amended

     (a)  in subsection (2) by striking out "5 years" and substituting
"15 years";

     (b)  by adding the following after subsection (2):

     (3)  For the purposes of subsection (2), "retain" includes the
conversion of a guarantee, given by Alberta Treasury Branches, into a loan.


     ------------------------------

     Alberta Regulation 165/2002

     Financial Consumers Act

     FINANCIAL CONSUMERS REGULATION

     Filed:  July 23, 2002

Made by the Lieutenant Governor in Council (O.C. 361/2002) on July 23, 2002
pursuant to section 49 of the Financial Consumers Act.


     Table of Contents

Definitions    1
Exempt named financial products    2
Exempt agents  3
Repeal    4
Expiry    5


Definition
1(1)  In this Regulation, "Act" means the Financial Consumers Act.

(2)  For the purposes of the Act, "securities dealer" means a person who is
registered as a dealer under the Securities Act.
     


Exempt named financial products
2   The following are not named financial products for the purposes of
section 2(i) of the Act:

     (a)  a contract of group insurance, as defined in the Insurance Act,
or any certificate issued under such a contract;

     (b)  a contract of creditor's group insurance, as defined in the
Insurance Act, or any certificate issued under such a contract;

     (c)  a pension plan, as defined in the Employment Pension Plans Act,
or any interest in such a plan;

     (d)  life insurance contracts that are exempt policies for the
purposes of the Income Tax Act (Canada).
     


Exempt agents
3   Section 17 of the Act does not apply to the following:

     (a)  an agent who is or is employed by a member of

               (i)  the Investment Dealers' Association of Canada,

               (ii) the Canadian Venture Exchange Inc.,

               (iii)     Bourse de Montreal Inc., or

               (iv) the Toronto Stock Exchange Inc.;

     (b)  an agent who is authorized in writing to issue a receipt in the
name of a supplier for which the supplier will accept responsibility;

     (c)  an agent who is registered to sell mutual funds under the
Securities Act.


Repeal
4   The Financial Consumers Regulation (AR 102/91) is repealed.


Expiry
5   For the purpose of ensuring that this Regulation is reviewed for
ongoing relevancy and necessity, with the option that it may be repassed in
its present or an amended form following a review, this Regulation expires
on June 30, 2012.


     Alberta Regulation 166/2002

     Government Organization Act

     COMMUNITY DEVELOPMENT GRANTS AMENDMENT REGULATION

     Filed:  July 23, 2002

Made by the Lieutenant Governor in Council (O.C. 362/2002) on July 23, 2002
pursuant to section 16 of the Government Organization Act.


1   The Community Development Grants Regulation (AR 57/98) is amended by
this Regulation.


2   Schedule 3 is repealed and the following is substituted:

     SCHEDULE 3

     COMMUNITY INITIATIVES PROGRAM GRANTS

1   The Minister may make grants under this Schedule to enhance and enrich
project-based community initiatives in community services, parks,
libraries, education, children's services, the environment, recreation and
sport, arts and culture, health, social services or seniors' services.


2(1)  An application for a grant under this Schedule must be submitted to
the Minister and be in a form specified by the Minister.

(2)  In addition to meeting the requirements of section 5 of this
Regulation, an applicant must also provide any additional information
required by the Minister.


3   The Minister may, after receiving an application, make a grant under
this Schedule to the applicant in an amount and on any conditions that the
Minister considers appropriate or may refuse the application.


4   An applicant is not eligible for more than one grant under this
Schedule in respect of the same project in the same fiscal year.


5(1)  A grant under this Schedule may be held unspent by the recipient of
the grant for a period of not more than 2 years from the date of issuance
of the grant payment, unless otherwise agreed to by the Minister.

(2)  A grant under this Schedule is to be accounted for separately in the
recipient's books and accounts and in the recipient's statement of revenues
and expenditures.

(3)  Any interest that accrues to a grant under this Schedule is to be
treated as part of the grant and must be used for the same purpose by the
grant recipient.


     ------------------------------

     Alberta Regulation 167/2002

     Persons with Development Disabilities
     Community Governance Act
     Financial Administration Act

     MICHENER CENTRE FACILITY BOARD TRANSFER
     OF GOVERNANCE REGULATION

     Filed:  July 23, 2002

Made by the Lieutenant Governor in Council (O.C. 363/2002) on July 23, 2002
pursuant to section 23 of the Persons with Developmental Disabilities
Community Governance Act and section 80 of the Financial Administration
Act.


Definition
1   In this Regulation, "Board" means the Michener Centre Facility Board.


Approval to wind up
2   The Lieutenant Governor in Council approves the winding up of the
Board.


Winding up
3   The activities of the Board are wound up and the activities are assumed
by the Central Region Community Board.


Transfer of assets and liabilities
4   The following applies:

     (a)  the property and assets of the Board are the property and
assets of the Central Region Community Board;

     (b)  the Central Region Community Board is liable for the
obligations and liabilities of the Board;

     (c)  an existing cause of action, claim or liability to prosecution
of, by or against the Board is unaffected and may be continued by or
against the Central Region Community Board;

     (d)  a civil, criminal or administrative action or proceeding
pending by or against the Board may be continued by or against the Central
Region Community Board;

     (e)  a conviction against, or ruling, order or judgment in favour of
or against the Board may be enforced by or against the Central Region
Community Board.